Go Deep
Sotac Pharmaceuticals Limited
Sotac Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,984 | 29.5 | 2.89 | 0.68 | 154.05 |
| Oct 2026 | 20,965 | 29.5 | 2.89 | 0.64 | 154.05 |
Sotac Pharmaceuticals Limited Quarterly Results
Quarterly data isn't available for this company right now.
Sotac Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,012,393,000.0 | 997,369,000.0 | 1,038,305,000.0 | 774,832,000.0 | — |
| Net Profit | 57,667,000.0 | 80,266,000.0 | 42,813,000.0 | 28,793,000.0 | — |
| EPS | — | 7.3 | 3.9 | 2.6 | 0.0 |
Sotac Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,334,704,000.0 | 1,243,282,000.0 | 1,053,269,000.0 | 736,390,000.0 | — |
| Total Liabilities | 688,986,000.0 | 659,059,000.0 | 559,982,000.0 | 539,535,000.0 | — |
| Total Equity | 588,748,000.0 | 532,519,000.0 | 452,592,000.0 | 194,593,000.0 | — |
Owes vs Owns
Sotac Pharmaceuticals Limited owed ₹0.52 for every ₹1 it owned in Mar 2026, down from ₹0.73 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.53× | 0.53× | 0.73× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sotac Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 0.9%Receivables 24.7%Inventory 20.3%Fixed assets (tangible) 35.6%Intangible assets 2.9%Long-term investments 2.2%Other assets 13.5%
How it's funded — Mar 2026
Short-term debt 20.4%Long-term debt 7.8%Payables 20.4%Other liabilities 3.1%Shareholders' equity 48.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1.2 | 1.8 | 3.4 | 9.7 |
| Receivables | 33.0 | 34.1 | 26.3 | 14.7 |
| Inventory | 27.1 | 20.3 | 18.0 | 13.6 |
| Fixed assets (tangible) | 47.5 | 47.0 | 38.7 | 24.0 |
| Intangible assets | 3.9 | 1.9 | 1.9 | 1.9 |
| Long-term investments | 2.9 | 3.8 | 2.1 | 0.0 |
| Other assets | 18.0 | 15.5 | 14.9 | 9.6 |
| Liabilities & equity | ||||
| Short-term debt | 27.2 | 29.5 | 12.7 | 14.3 |
| Long-term debt | 10.4 | 14.2 | 12.1 | 7.8 |
| Payables | 27.2 | 18.9 | 28.9 | 25.4 |
| Other liabilities | 4.1 | 3.3 | 2.2 | 6.5 |
| Shareholders' equity | 64.6 | 58.4 | 49.3 | 19.7 |
| Net tangible assets | 55.0 | 51.3 | 43.3 | 17.6 |
Sotac Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 168,532,000.0 | -43,500,000.0 | -160,756,000.0 | 81,426,000.0 | — |
| Investing Activities | -68,976,000.0 | -136,159,000.0 | -196,793,000.0 | -116,738,000.0 | — |
| Financing Activities | -103,416,000.0 | 161,120,000.0 | 294,911,000.0 | 131,362,000.0 | — |